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Abstract
Trigeminal neuralgia is a representative neuropathic facial pain condition, characterised by unilateral paroxysmal pain in 
the distribution territory of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli. A subgroup of 
patients with trigeminal neuralgia [TN (previously defined as atypical TN)] also suffer from concomitant continuous pain, 
i.e. a background pain between the paroxysmal attacks. The aim of this review is to provide current, evidence-based, knowl-
edge about the pharmacological treatment of typical and atypical TN, with a specific focus on drugs in development. We 
searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials 
database (ClinicalTrials.gov), taking into account publications up to February 2018. Two authors independently selected 
studies for inclusions, data extraction, and bias assessment. Carbamazepine and oxcarbazepine are the first-choice drugs 
for paroxysmal pain. When sodium channel blockers cannot reach full dosage because of side effects, an add-on treatment 
with lamotrigine or baclofen should be considered. In patients with atypical TN, both gabapentin and antidepressants are 
expected to be efficacious and should be tried as an add-on to oxcarbazepine or carbamazepine. Although carbamazepine and 
oxcarbazepine are effective in virtually the totality of patients, they are responsible for side effects causing withdrawal from 
treatment in an important percentage of cases. A new, better tolerated, Nav1.7 selective state-dependent, sodium channel 
blocker (vixotrigine) is under development. Future trials testing the effect of combination therapy in patients with TN are 
needed, especially in patients with concomitant continuous pain and in TN secondary to multiple sclerosis.
Key Points 
Carbamazepine and oxcarbazepine are the first-choice 
drugs for paroxysmal pain in patients with trigeminal 
neuralgia.
These drugs, effective in virtually all patients, produce 
side effects causing withdrawal from treatment in about 
20% of cases.
A new, better tolerated, Nav1.7 selective state-depend-
ent, sodium channel blocker is under development.
Currently there is a lack of evidence for most effective 
medications in patients affected by TN with concomitant 
continuous pain; these patients may benefit from medica-
tions used for neuropathic pain.
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1 Introduction
Trigeminal neuralgia (TN) is a representative neuro-
pathic facial pain condition, characterised by unilateral 
paroxysmal pain described as stabbing or electric shock-
like, in the distribution territory of one or more divi-
sions of the trigeminal nerve and triggered by innocuous 
stimuli [1].
According to the new classification and diagnostic 
grading of TN issued by the International Association for 
the Study of Pain (IASP), TN is distinguished in three 
diagnostic categories—classical, caused by vascular com-
pression producing anatomical changes in the trigeminal 
nerve root—secondary, due to an identifiable underlying 
neurologic disease,—idiopathic, when even after MRI or 
other investigation, the aetiology of TN remains unclear 
(Table 1) [2].
Regardless of the aetiology, the primary mechanism of 
paroxysmal pain is the same, i.e. a focal demyelination of 
primary trigeminal afferents near the entry of the trigeminal 
root into the pons, making the axons hyper-excitable and 
increasing the susceptibility to ectopic excitation, ephaptic 
transmission, and high-frequency discharges [3–5].
TN has an annual incidence of three to five per 100,000. 
It is more common in women than men (age adjusted ratio: 
1.74:1) and in people aged 50–69 years [6, 7].
In virtually the entire population of patients with TN, 
at least one trigger capable of provoking a paroxysm can 
be identified. In a recent study, provocation of paroxysmal 
pain by various trigger manoeuvres was reported by 136 
of the 140 patients. The most frequent manoeuvres were 
gentle touching of the face and talking. Trigger zones were 
predominantly reported in the perioral and nasal region and 
were variable in size [8]. These data are coherent with the 
use of trigger factor as an essential diagnostic feature for a 
clinically established diagnosis of TN [2]. Patients with TN 
may suffer from different types of pain, ranging from single 
attacks to a series of prolonged attacks, and it was suggested 
that these pain characteristics can vary over time [9].
Traditionally, autonomic symptoms such as tearing and 
rhinorrhoea have not been associated with TN. However, it 
is now known that a large proportion of TN patients have 
autonomic symptoms [10].
A subgroup of patients with TN also suffer from con-
comitant continuous pain (CCP), described as dull, burn-
ing or aching [11]. This condition has been described with 
several definitions, including atypical TN and TN type 2; 
the International Headache Society Classification (ICHD) 
[1] defined this relatively uncommon type of TN as TN 
with concomitant continuous facial pain. The presence of 
continuous pain is not related to aetiology and may occur 
in idiopathic, classic, or secondary TN. Background pain 
Table 1  Trigeminal neuralgia diagnostic criteria
IASP International Association for the Study of Pain, ICHD International Classification of Headache Disorders, MS multiple sclerosis, TN 
trigeminal neuralgia
IASP criteria
 Definition TN is orofacial pain restricted to one or more divisions of the trigeminal nerve. With the exception of TN caused by MS, 
the pain affects one side of the face. It is abrupt in onset and typically lasts only a few seconds (2 min at maximum). 
Patients may report their pain as arising spontaneously, but these pain paroxysms can always be triggered by innocuous 
mechanical stimuli or movements. Patients usually do not experience pain between paroxysms. If they do report addi-
tional continuous pain, in the same distribution and in the same periods as the paroxysmal pain, they are considered to 
have TN with continuous pain
 Classification Classical TN: caused by vascular compression of the trigeminal nerve root resulting in morphological changes of the root
Secondary TN: caused by major neurological disease, e.g. a tumor of the cerebellopontine angle or MS
Idiopathic TN: no apparent cause
ICHD criteria
 Criteria A. At least three attacks of unilateral facial pain fulfilling criteria B and C
B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal distribution
C. Pain has at least three of the following four characteristics:
 1. recurring in paroxysmal attacks lasting from a fraction of a second to 2 min
 2. severe intensity
 3. electric shock-like, shooting, stabbing or sharp in quality
 4. precipitated by innocuous stimuli to the affected side of the face
D. No clinically evident neurological deficit
E. Not better accounted for by another ICHD-3 diagnosis
 Classification 13.1.1.1 Classical TN (classical TN, purely paroxysmal; classical TN with concomitant continuous pain)
13.1.1.2 Secondary TN (TN attributed to MS; TN attributed to space-occupying lesion; TN attributed to other cause
13.1.1.3 Idiopathic TN (idiopathic TN, purely paroxysmal; idiopathic TN with concomitant continuous pain
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distribution coincides with that of the paroxysmal pain, and 
fluctuations of its intensity parallel in time those of the par-
oxysmal pain [12, 13]. A prevalence three times higher in 
women than in men was reported [11]. In a cohort of 158 
patients with TN, continuous pain developed within a mean 
period of 1.5 years since the disease onset, thus suggesting 
that this kind of pain is not a consequence of a long duration 
of stabbing pain [11]. The mechanisms underlying continu-
ous pain, as opposed to paroxysmal pain, are not fully under-
stood, with implications for treatment. There is the evidence 
that continuous and paroxysmal pain may improve differ-
ently after microvascular decompression, thus supporting the 
hypothesis that the mechanisms responsible for the two pain 
components may be different [14–17]. Central mechanisms 
[18] and progressive root damage due to compression [19] 
have been proposed as possible factors.
Carbamazepine (CBZ) and oxcarbazepine (OXC) are the 
first-choice medical treatment in TN. They have the same 
mechanism of action, the blockade of voltage gated sodium 
channel in a frequency dependent manner, resulting in the 
stabilization of hyperexcited neural membranes and in the 
inhibition of repetitive firing. In patients with purely par-
oxysmal pain, CBZ and OXC are effective in virtually the 
entire patient population. However, they produce side effects 
to a level that cause interruption of treatment or a dosage 
reduction in 23% of patients [20], making necessary the 
development of new, more selective sodium channel block-
ers. Conversely in patients with CCP, the efficacy of CBZ 
and OXC may drop, thus suggesting the opportunity to test 
the efficacy of different drug categories. A wide range of 
drugs has been investigated in TN, but the scientific litera-
ture highlighted the need of high quality clinical trials in 
TN [21].
The aim of this review, based on a systematic search of 
relevant literature, is to provide current, evidence-based, 
knowledge about the pharmacological treatment of typical 
and atypical TN, with a specific focus on drugs in develop-
ment, such as botulinum toxin A and new, more selective 
sodium channel blockers.
2  Search Process
We searched for relevant papers within the PubMed, 
EMBASE and the Cochrane Database of Systematic 
Reviews, taking into account publications up to Febru-
ary 2018. All searches used the following synonyms for 
TN: trigeminal neuralgia and tic douloureux. The primary 
search was supplemented by a secondary search using the 
bibliographies of the retrieved articles. Only full-length, 
original communications including open-label studies were 
considered, and the search was limited to English language 
publications. Clinical trials database (ClinicalTrial.gov) 
has been checked in order to include in the analysis stud-
ies currently in progress. The review process was carried 
out independently by two reviewers and only publications 
independently approved by the two authors were taken into 
account (Supplementary Material 1). The authors indepen-
dently assessed the quality of the individual trials during 
data extraction. Inclusion criteria were the following: trials 
including patients with a diagnosis of typical or atypical 
TN, including classical, idiopathic and secondary TN, and 
a minimum sample of 10 patients.
3  Drugs in Classical or Idiopathic Trigeminal 
Neuralgia
3.1  First‑line Treatment
CBZ and OXC are the first-line treatment in TN. Their effect 
is related to the blockade of voltage-sensitive sodium chan-
nels in a frequency dependent manner, resulting in the sta-
bilization of hyperexcited neural membranes and inhibition 
of repetitive firing.
Systematic reviews and randomised controlled trials, 
including 147 patients [22–29], demonstrated the efficacy 
of CBZ compared to placebo, with a number-needed-to-
treat (NNT) to obtain pain relief of 1.7–1.8. However, CBZ 
showed a number-needed-to-harm (NNH) of 3.4 for minor 
and 24 for severe adverse events [24]. In the study of Killian 
and Fromm [26], with a maximum daily dose of 1000 mg, 19 
of 27 participants had a complete or very good response with 
CBZ compared with minimal or no response with placebo 
on a 5-day treatment. Nicol [27], using a cross-over design 
and a maximum daily dose of 2400 mg, reported that 15 of 
20 participants randomised to initial CBZ had a good or 
excellent response after 14 days’ treatment, compared with 
6 of 24 reporting good or excellent response who started on 
placebo. Superiority of CBZ was also reported by Rock-
liff and Davis [28] in a small sample of patients with three 
days’ treatment with CBZ. In the study from Rasmussen 
and Riishede [29], after 5 days’ treatment, 46 of 55 patients 
with TN had good effect on CBZ, compared with 8 of 55 on 
placebo. Campbell and colleagues [25] reported a mean fall 
in maximum pain intensity of 58% after 2 weeks treatment 
with CBZ 400–800 mg daily compared to 26% with placebo 
(Supplementary Material 1).
Compared to CBZ, OXC showed a similar efficacy in 
reducing pain attacks but a greater tolerability and a lower 
potential for drug interaction [30]. However, data from full 
randomised controlled trials are not available, thus preclud-
ing the NNT and NNH calculation.
A pilot study on OXC with extended-release formula-
tion is currently in progress (ClinicalTrials.gov Identifier: 
NCT03374709).
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3.2  Alternative Treatments
3.2.1  Lamotrigine
Lamotrigine acts at level of the voltage-sensitive sodium 
channels, stabilises neural membranes and inhibits the 
release of excitatory neurotransmitters. Two systematic 
reviews [23, 31] identified a small double-blind crossover 
randomised controlled trial comparing lamotrigine ver-
sus placebo in 14 patients receiving CBZ or phenytoin. 
Patients continued to take a steady dose of CBZ or pheny-
toin throughout the trial over a 31-day period. Each arm of 
the trial lasted 2 weeks with an intervening 3-day washout 
period. The maintenance dose of lamotrigine was 400 mg. 
This study showed that lamotrigine in combination with 
CBZ or phenytoin was slightly more effective than placebo. 
The adverse reactions with both lamotrigine and placebo 
were predominantly dose-dependent effects on the central 
nervous system (CNS). One patient withdrew from the study 
due to severe pain during the placebo arm of the trial [32].
A crossover study involving 21 patients with TN com-
pared lamotrigine (400 mg) with CBZ (1200 mg) [33]. 
CBZ reduced pain in 90.5% (19/21) and lamotrigine in 62% 
(13/21) of the patients using both visual analogue scale 
(VAS) and verbal rating scale. The reported side effects were 
headache, dizziness and skin rash.
3.2.2  Baclofen
Two studies tested the efficacy of baclofen in TN [34, 35]. 
This drug is a  GABAB receptor agonist and depresses excita-
tory neurotransmission. Baclofen was superior to placebo in 
reducing the number of painful paroxysms in a randomised 
controlled trial including ten participants; baclofen signifi-
cantly decreased the number of painful paroxysms in seven 
patients [34]. A double-blind crossover trial in 15 patients 
showed that l-baclofen was more effective than five times 
as much racemic baclofen in nine patients. Six of these 
nine patients have continued pain-free on l-baclofen for 
4–17 months (mean, 10 months). l-baclofen was much better 
tolerated than racemic baclofen [35]. However, these stud-
ies showed several limitations, such as the small sample of 
patients and the short duration of treatment, so the results 
must be interpreted with caution.
3.2.3  Pimozide, Tizanidine and Tocainide
One systematic review [36] identified three randomised con-
trolled trials comparing pimozide [37], tizanidine [38] and 
tocainide [39] with CBZ. Pimozide was more effective than 
CBZ in a double-blind crossover 24-week trial including 48 
patients suffering from refractory TN but significant side 
effects of this neuroleptic drug, including CNS disturbances, 
hand tremors and memory impairment were reported [37]. 
The effect of tizanidine, a centrally acting alpha-adrener-
gic agonist, in comparison with CBZ was tested in a very 
small sample of patients. After individual titration of tiza-
nidine and CBZ, the maximum daily doses were 18 mg and 
900 mg, respectively, and the difference was not statistically 
significant [38]. Tocainide, a sodium channel blocker with 
anti-arrhythmic action, was tested in 12 participants in a 
double-blind cross-over study for 2 weeks, but significant 
side effects limited its use [39].
3.2.4  Calcium Channel Blockers
The efficacy of calcium channel blockers, gabapentin and 
pregabalin, has been assessed in small controlled or open-
label studies. These drugs exert their pharmacodynamic 
effect by modulating voltage-gated calcium channels and 
thus reducing release of excitatory neurotransmitters.
One systematic review and meta-analysis [40] identi-
fied 16 randomised controlled trials, all published in Chi-
nese, on the efficacy of gabapentin in comparison with 
CBZ in the treatment of TN. 1331 patients were included 
and VAS score was used to assess the effect of treatment. 
The total effective rate of gabapentin therapy group was 
similar with CBZ therapy group and the adverse reaction 
rate of gabapentin therapy group was significantly lower 
than that of CBZ. However, the authors concluded that the 
trials are all poor in terms of methodological quality [40].
Pregabalin was not tested in randomised controlled tri-
als. An open-label study including 53 patients showed the 
efficacy of pregabalin in reducing TN by over 50% in 74% 
of patients [41]. Two observational studies, including 65 
patients, proved the efficacy of pregabalin in monotherapy 
(n = 36) or add-on (n = 29) for 12 weeks. However, according 
to the inclusion criteria, patients with an atypical facial pain 
might also have been included [42, 43].
In an open-label crossover trial involving 22 patients with 
refractory TN using lamotrigine and pregabalin together 
with CBZ, pregabalin showed a comparable efficacy and a 
better patient tolerance than lamotrigine [44].
3.2.5  Levetiracetam
Among anticonvulsants, open label studies investigated 
the efficacy of levetiracetam. A pilot study investigated 
the efficacy and tolerability of this drug in 10 patients with 
TN over a period of 10 weeks. Patients were treated with 
up to 4000 mg daily and 40% reported an improvement 
of 50%–90% [45]. In an observational trial, including 23 
patients with refractory TN, levetiracetam (3–4 g/day) for 
16 weeks decreased the number of daily attacks by 62.4% 
[46].
1437Treating Trigeminal Neuralgia
3.2.6  Eslicarbazepine
Eslicarbazepine, a third-generation antiepileptic drug 
belonging to the dibenzazepine group, targets the voltage-
gated sodium channels and is currently approved as adjunct 
therapy for focal seizures. A recent retrospective, open-label, 
multicentric, intention-to-treat study assessed the efficacy 
and safety of this drug in patients with TN. Eighteen par-
ticipants were included; the dose of eslicarbazepine ranged 
between 200 and 1200 mg/day. Responder rate was 88.9%; 
71% of patients presented some adverse events and four 
patients discontinued the treatment [47].
3.2.7  Local Anaesthetics
Two randomised controlled trials investigated the effect of 
local anaesthesia injected into trigger area [48, 49]. These 
studies, combining the peripheral analgesic block with ropi-
vacaine and CBZ or gabapentin, showed improved outcome. 
In the randomised controlled trial combining the peripheral 
analgesic block with ropivacaine and CBZ in 45 patients, 
the association protocol resulted in a significant reduction 
in pain intensity, number of daily pain paroxysms and daily 
dose of CBZ intake, when compared with CBZ in mono-
therapy [48].
In the randomised controlled trial in 36 patients com-
bining gabapentin with ropivacaine injection into trigger 
areas showed improved pain control and quality of life 
[49]. The association treatment was safe, without side 
effects and resulted in an important clinical benefit with 
an improvement of the functional health status of TN 
patients when compared with gabapentin alone. A reduc-
tion of VAS score after 7 and 28 days of treatment was 
reported, and this effect was still present 6 and 12 months 
later. The NNT (gabapentin + ropivacaine vs gabapentin 
protocols) to obtain 1 gabapentin + ropivacaine-treated 
patient with at least 50% pain relief was 1.71 (day 7) and 
2.40 (day 28).
Two randomised controlled trials tested the short-term 
effect of topical 8% lidocaine versus placebo in TN [50, 51]. 
In the study of Kanai et al. [50], including 25 patients with 
TN involving the second division, those given an 8% spray 
of lidocaine as opposed to saline had a statistically signifi-
cant decrease in pain. The effect of treatment persisted for a 
mean of 4 h without serious adverse reactions. In the study 
of Niki et al. [51], including 24 patients with TN and severe 
intraoral pain, the application on the painful areas of 8% 
lidocaine significantly reduced the NRS score of paroxysmal 
pain for a mean of 3 h, without serious side effects. However, 
these studies showed several criticisms and the findings must 
be interpreted with care.
3.2.8  Sumatriptan
Recent studies tested the effect of 5-HT1A/1B/1D recep-
tor agonist on pain relief in patients with TN. These drugs 
may inhibit vasodilation and inflammation near the demy-
elinated trigeminal root. Two randomised controlled trials 
tested the effect of subcutaneous injection of sumatriptan 
3 mg and the oral administration of 50 mg twice daily [52, 
53]. Fifteen minutes after injection of sumatriptan, the base-
line VAS decreased from 8.3 to 2.4 cm. At the end of oral 
treatment, the VAS was significantly decreased, and this 
effect persisted after treatment discontinuation for a further 
week. However, the side effects related to a long-term use, 
including a triptan overuse headache, exclude the use of 
sumatriptan in the long-term treatment of TN.
3.3  Intravenous Drugs for Acute Exacerbations
In a randomised controlled trial including 20 patients with 
intractable TN, a single dose of intravenous lidocaine (5 mg/
kg over 60 min) was superior in reducing pain intensity com-
pared to placebo during the first 24 h after the infusion [54].
3.4  Drugs Under Development
3.4.1  Vixotrigine
A new Nav1.7 selective state-dependent, sodium channel 
blocker (vixotrigine) is under development. Nav1.7, a major 
sodium receptor in the nociceptive system, is not located in 
the brain, thus preventing any side effects associated with 
depression of CNS excitability [55]. A Phase 1 study dem-
onstrated the good tolerability of vixotrigine, administered 
at therapeutic doses without lengthy titration. The new drug 
was tested in a double-blind, placebo-controlled, randomised 
withdrawal Phase 2a trial, including 67 patients with clas-
sical and idiopathic TN [21]. After a 7-day run-in phase, 
eligible patients received open-label, vixotrigine 150 mg 3 
times per day, orally, for 21 days. Patients who met at least 
one response criteria were then randomly assigned (1:1) to 
vixotrigine or placebo for up to 28 days in a double-blind 
phase. Although the primary endpoint of treatment failure 
was not significantly lower in the vixotrigine group than in 
the placebo group, significant treatment differences ver-
sus placebo in secondary endpoints were found, including 
time to treatment failure, number of paroxysms and average 
daily pain score. The new drug was well tolerated, and no 
severe or serious adverse events were reported. A Phase 3 
placebo-controlled, double-blind randomised withdrawal 
study is currently in progress (ClinicalTrials.gov Identifier: 
NCT03070132).
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3.5  Presurgical Procedures
3.5.1  Botulinum Toxin A
Botulinum toxin type A (BTX-A), an exotoxin released by 
the gram-positive bacterium Clostridium botulinum, is sup-
posed to block the TRPV1 receptor of unmyelinated C fibre 
terminals and limit the release of substance P, calcitonin 
gene-related peptide and glutamate from presynaptic termi-
nals of the primary sensory neurons.
A systematic review [56] identified 4 randomised con-
trolled trials, on 178 patients, testing the effect of BTX-A 
in patients with TN [57–60]. The total dosage adminis-
tered varies from 25U to 75U and the number of injections 
from 8 to 20. The injections were administered intrader-
mally and/or submucosally where pain was experienced 
according to the patient’s description. The overall effect 
favoured BTX-A versus placebo in terms of proportion of 
responders; paroxysms frequency per day was significantly 
lower for BTX-A group. The duration of effect was rela-
tively long (at least 3 months). Adverse events included 
transient facial weakness, oedema and haematoma at the 
site of injection. Despite these encouraging findings, 
future studies assessing the optimal dose, duration of the 
therapeutic efficacy, adverse events, the time and indica-
tions for repeat injection are required. To our knowledge, 
no data are available about the effect of repeated BTX-A 
injections in TN.
A clinical trial comparing intradermal/submucosal injec-
tion and intra-masseter injection of BTX-A is currently in 
progress (ClinicalTrials.gov Identifier: NCT03331913).
3.5.2  Intranasal Non‑inhaled Carbon Dioxide
Recently,  CO2 has been shown to be a modulator of acti-
vated nociceptive trigeminal neurons [61]. Based on animal 
model, an antinociceptive effect of intranasal  CO2 by acti-
vation of mucosal primary trigeminal afferents through a 
decreased mucosal pH was postulated [62]. A controlled, 
randomised, parallel-group study investigated the effects 
of intranasal  CO2 on TRPV1-mediated trigeminal pain in 
healthy volunteers. Only mild modulatory effect of intrana-
sal insufflation of  CO2 at flow rates of 1 L/min was found, 
and the clinical utility seemed limited since changes in pain 
ratings were therapeutically irrelevant [63]. A Phase 2 pla-
cebo-controlled, single-blind study to evaluate the safety and 
efficacy of nasal  CO2 has been conducted in patients with 
classical TN. All subjects received 3 doses of active and 3 
doses of placebo. A single dose consisted of a 60-second 
delivery of  CO2 or placebo. The primary outcome was pain 
relief assessed on VAS. Recruitment phase is completed; 
however, the study findings have not yet been published 
(ClinicalTrials.gov Identifier: NCT02473016).
4  Drugs in Secondary Trigeminal Neuralgia
No randomised controlled trials were found in patients with 
secondary TN. The existing studies based on CBZ, OXC, 
eslicarbazepine, lamotrigine, gabapentin, pregabalin, topira-
mate and misoprostol have an open label design and include 
small sample of patients with multiple sclerosis (MS) [47, 
64–78]. Only few studies provided details about the type of 
MS and the TN diagnostic criteria [78]. One study used a 
VAS and recorded both intensity and number of attacks [75, 
78]. These case series reported the potential efficacy of lam-
otrigine as monotherapy or in association with gabapentin 
or CBZ, topiramate and gabapentin. Three studies reported 
the efficacy of misoprostol (a prostaglandin-E1-analogue) 
in a total of 27 patients with TN secondary to MS [74–76]. 
According to the international guidelines [22], there is insuf-
ficient evidence to support or refute the effectiveness of any 
medication in treating pain in TN secondary to MS.
5  Drugs in Trigeminal Neuralgia 
with Concomitant Continuous Pain
No clinical trials assessing pharmacological treatment of 
CCP in TN have been conducted. Different studies clearly 
demonstrated that continuous pain is associated with poor 
medical and surgical outcome [11, 14, 43]. Recently, in a pro-
spective study including 158 patients with TN (also including 
patients with CCP), the prevalence of responders to sodium 
channel blockers was lower in the group with also CCP [10]. 
On the basis of these data, constant pain is considered a pre-
dictor of poor treatment response. No study has assessed the 
drug effect in reducing constant and paroxysmal pain inten-
sity separately. Because CBZ and OXC are extremely effica-
cious in increasing the refractory period of action potentials, 
they act on the high frequency discharges that characterise 
the paroxysms of TN. Usually, in patients with also continu-
ous pain mediated by other pathophysiological mechanisms, 
a monotherapy with sodium channel blocker is not sufficient 
to control pain and other drugs are usually needed. As far 
as we know, calcium channel blockers and antidepressants, 
whose efficacy has already been proven in the treatment of 
neuropathic continuous pain due to several aetiologies, have 
never been systematically tested in TN patients with CCP. 
Future randomised controlled trials assessing these drugs as 
add-on treatment in TN with CCP are required.
6  Expert Opinion
Based on evidence [22], CBZ (400–1200 mg/day) and 
OXC (900–1800  mg/day) are the first-choice medical 
treatment in TN. OXC should be preferred for better 
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tolerability and the decreased potential for drugs interac-
tions. These drugs are effective in most patients and the 
development of late resistance only occurred in a very 
small minority of patients. However, the side effects cause 
withdrawal from treatment in an important percentage of 
patients [20]. Common initial side effects include drowsi-
ness, nausea, dizziness, diplopia, ataxia and elevation of 
transaminases. Hyponatraemia occurs in 6–8% of patients; 
sodium levels are dose related and should be monitored 
during the treatment, especially when high dosage is used. 
Patients treated with diuretics may be more susceptible to 
developing sodium depletion [14]. The addition of sodium 
chloride capsules can be helpful in patients with persistent 
hyponatremia. Serious but uncommon side effects include 
allergic rash, hepatotoxicity, lymphadenopathy, systemic 
lupus erythematosus, Stevens–Johnson syndrome and 
aplastic anaemia. Specific contraindications are cardiac 
conduction problems or severe arrhythmias.
In a prospective, observational, exploratory survey of 
161 patients with idiopathic TN, females treated with CBZ 
or OXC reported significantly more side effects than males 
[79]. Pharmacokinetic and pharmacodynamic differences 
are likely to be the reason for gender differences in report-
ing side effects.
The consumers’ views on treatments used for TN was 
investigated by using a self-administered questionnaire 
distributed to 133 patients and 21 clinicians attending 
national support group meetings in the USA and UK [80]. 
All patients reported at least one side effect. The clinicians 
underestimated the number of side effects, but both groups 
agreed that drowsiness and cognitive impairment were the 
most disliked side effects.
A prospective study investigated the risk and genetic asso-
ciation of OXC-induced cutaneous adverse reactions, includ-
ing Stevens–Johnson syndrome/toxic epidermal necrolysis, 
in Asian populations. The authors found that HLA-B*15:02 
was significantly associated with OXC-Stevens-Johnson syn-
drome in Chinese and Thai populations [81].
CBZ is a potent inducer of CYP3A4 and other oxidative 
enzyme systems in the liver, and it may also increase glu-
curonyl transferase activity, leading to a number of clini-
cally relevant drug interactions. OXC, a keto-analogue of 
CBZ, rapidly converted into its pharmacologically active 
metabolite, should be preferred for the better tolerability 
and the decreased potential for drugs interactions.
A recent meta-analysis investigating the teratogenic 
effects of different antiepileptic drugs showed that chil-
dren exposed to CBZ were at a higher risk of malformation 
than children born to women without, and women with 
untreated epilepsy [82].
Vixotrigine, a new sodium channel blocker that is selec-
tive for the Nav1.7 receptor is under development and has 
promise of efficacy without inducing side effects related to 
CNS depression [21].
Lamotrigine is considered a second-line treatment 
in patients with TN. Potential side effects of lamotrigine 
include dizziness, nausea, blurred vision and ataxia. Approx-
imately 7–10% of patients will report a skin rash during the 
first 48 weeks of therapy [32]. The dose of lamotrigine must 
be increased slowly in order to avoid skin rash.
In patients with refractory TN, or in the event of with-
drawal due to side effects, surgery should at least be pro-
posed and discussed with the patient.
In refractory TN, BTX-A is a promising alternative treat-
ment option that might spare the need for surgical interven-
tions [83]. Although it is reasonable that BTX-A primar-
ily acts on constant pain, to our knowledge, no study has 
reported the effects of injections in a subgroup of patients 
with CCP until now.
During acute exacerbation, in-hospital treatment may be 
necessary for rehydration, management of hyponatraemia, 
titration of drugs, and, in selected case, lidocaine or fosphe-
nytoin intravenous infusion, under specialist supervision and 
cardiac monitoring. Intravenous loading of fosphenytoin was 
reported in case series but no randomised controlled trials 
have been conducted until now [7, 84–86].
The first-line therapy in secondary TN is based on sodium 
channel blockers. In patients with MS-related TN, gabap-
entin, lamotrigine and topiramate represent other thera-
peutic options, but the quality of evidence is poor. In this 
patient category pharmacological treatment may potentiate 
some of the MS symptoms with a high dropout rate. Expert 
consensus suggests that baclofen may be useful in patients 
with MS who develop TN. Such patients are often taking 
baclofen already to reduce spasticity and may achieve con-
trol of symptoms without having to add CBZ. The main side 
effects of baclofen are transient sedation and loss of muscle 
tone. Abrupt discontinuation may cause seizures and hal-
lucinations [87].
In patients with TN, CCP is associated with poor medical 
and surgical outcome. In this condition, both calcium chan-
nel blockers (gabapentin and pregabalin) and antidepressants 
may be efficacious and should be tried as an add-on to OXC 
or CBZ. However, randomised, controlled, double-blinded 
trials are still lacking.
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